StockData

Precision BioSciences vs Metagenomi Therapeutics

DTIL and MGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DTIL and MGX compare

Precision BioSciences is the larger company, worth 8.2 times as much as Metagenomi Therapeutics ($195M against $23.8M).

Metagenomi Therapeutics scores higher on the StockData Score (6 against 4 for Precision BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDTILMGX
Size and price
Market cap$195M$23.8M
Share price$7.05$0.631
Change, 1 year19.9%−63.7%
Change, 5 years−97.4%–
Beta (5Y)−0.531.85
Employees68119
StockData Score
Total score46 (better)
Valuation score01 (better)
Growth score2 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S4.3×–
P/B4.3×0.2× (better)
FCF yield−26.7% (better)−360%
Fair value$4.46–
Margin of safety−58.2%–
Growth
Revenue growth (TTM)3473%–
Revenue growth, 5Y average7.1%–
Profitability
Operating margin−80.8%–
Net margin−117%–
FCF margin−115%–
Return on equity−133%−60.6% (better)
Financial health
Debt / equity–0.00
Interest coverage−27.6×–
Current ratio12.82 (better)4.50
Altman Z-score−4.78−3.92 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions64.0%16.6%
Held by insiders3.0%10.4%
Insider net buying, 12 months−$396K−$9.7K (better)
Short interest, % of float7.8%3.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.